Therapeutically, ideal outcomes were achieved in different tumour models, including in immunodeficient NOD-SCID mice, which further support that combining IFN-γ and an IDO1 or AhR inhibitor directly target dormant TRCs. The gene discussed is IFNG; the disease is neoplasm.